PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsToripalimab
Toripalimab
Loqtorzi (toripalimab) is an antibody pharmaceutical. Toripalimab was first approved as Loqtorzi on 2023-10-27. It is used to treat nasopharyngeal carcinoma in the USA. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
stomatognathic diseasesD009057
otorhinolaryngologic diseasesD010038
Trade Name
FDA
EMA
Loqtorzi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Toripalimab
Tradename
Proper name
Company
Number
Date
Products
Loqtorzitoripalimab-tpziCoherus OncologyN-761240 RX2023-10-27
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
loqtorziBiologic Licensing Application2026-07-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
nasopharyngeal carcinoma—D000077274—
Agency Specific
FDA
EMA
Expiration
Code
toripalimab, Loqtorzi, Coherus BioSciences, Inc.
2030-10-27Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
736 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nasopharyngeal neoplasmsD009303——937211162
Breast neoplasmsD001943EFO_0003869C5052511434
Biliary tract neoplasmsD001661—C24.9215—1118
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0116611—1494
NeoplasmsD009369—C8069541—393
Non-small-cell lung carcinomaD002289——17459—266
Nasopharyngeal carcinomaD000077274——84222—166
Hepatocellular carcinomaD006528—C22.010247—1651
Liver neoplasmsD008113EFO_1001513C22.08225—1444
Esophageal squamous cell carcinomaD000077277——5316—544
Squamous cell carcinomaD002294——4282—436
Squamous cell carcinoma of head and neckD000077195——7293——34
MelanomaD008545——13201—333
Show 29 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——1021——430
Pancreatic neoplasmsD010190EFO_0003860C2568———11
Head and neck neoplasmsD006258——29———10
Kidney neoplasmsD007680EFO_0003865C6445———8
Hypopharyngeal neoplasmsD007012—C13—7———7
SarcomaD012509——27———7
Ovarian neoplasmsD010051EFO_0003893C5615———5
Laryngeal neoplasmsD007822EFO_0003817C32—5———5
Oropharyngeal neoplasmsD009959———3——14
Colonic neoplasmsD003110—C1813———3
Show 66 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.82————2
TransplantationD014180——1————1
Liver transplantationD016031EFO_0010682—1————1
Brain neoplasmsD001932EFO_0003833C711————1
Prostatic neoplasmsD011471—C611————1
Lymphoproliferative disordersD008232Orphanet_2442D47.91————1
LeukemiaD007938—C951————1
Myeloid leukemia acuteD015470—C92.01————1
Myeloid leukemiaD007951—C921————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K77————11
Female genital neoplasmsD005833——————11
Abdominal neoplasmsD000008——————11
Transplantation chimeraD018183——————11
Acute kidney injuryD058186—N17————11
Catheter ablationD017115——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameToripalimab
INNtoripalimab
Description
Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>6JBT:H|Heavy chain QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAY MELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV >6JBT:L|Light chain DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKI SRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB6JBT
CAS-ID1924598-82-2
RxCUI—
ChEMBL IDCHEMBL4297843
ChEBI ID—
PubChem CID—
DrugBankDB15043
UNII ID8JXN261VVA (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Toripalimab – Coherus Oncology
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,753 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,164 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use